CSL strikes rare-disease drug deal worth up to $1.6 billion with Alentis

Reuters reports that Australia’s CSL agreed with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases. The deal is worth up to $1.6 billion before development funding.